← Back to Search

Procedure

UVA-1 Therapy for Sclerosing Skin Diseases

N/A

Waitlist Available

Led By Christopher B. Hansen, M.D.

Research Sponsored by University of Utah

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age of at least 18-years-old

Must have a diagnosis of systemic scleroderma with cutaneous sclerosis, morphea, or sclerodermatous Graft vs. host disease based on the presence of characteristic clinical findings

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 100 days

Awards & highlights

Study Summary

This trial is meant to study how well UVA-1 therapy improves patient reported outcomes in those with sclerosing skin diseases.

Who is the study for?

This trial is for adults over 18 with sclerosing skin diseases like systemic scleroderma, morphea, or Graft-Versus-Host Disease affecting the skin. Participants must be able to complete 30 UVA-1 therapy sessions within 100 days and provide consent. Pregnant individuals, those intolerant to UV light, or who have used UV therapy/tanning beds in the last month cannot join.Check my eligibility

What is being tested?

The study aims to measure patient-reported improvements after undergoing 30 sessions of UVA-1 phototherapy for treating sclerosing skin conditions. It's a prospective trial where patients self-report outcomes and undergo clinical assessments before and after treatment.See study design

What are the potential side effects?

Potential side effects may include reactions related to ultraviolet light exposure such as redness, irritation or burns on the treated areas of skin. Long-term risks could involve premature aging of the skin or an increased risk of certain types of skin cancer.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have been diagnosed with systemic scleroderma or similar skin hardening conditions.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 100 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~100 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 100 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Evaluate change in the Health Assessment Questionnaire Disability Index (HAQ-DI) after 30 sessions of UVA-1 therapy in treating systemic Scleroderma, morphea, and sclerodermatous graft vs. host disease.

Secondary outcome measures

Assess changes in durometer scores in all patients after 30 sessions of UVA-1 therapy.

Assess changes in the Hand Mobility in Scleroderma (HAMIS) score in patients with hand involvement after 30 sessions of UVA-1 therapy.

Assess changes in the Localized Scleroderma Assessment Tool (LoSCAT) score in morphea patients after 30 sessions of UVA-1 therapy.

+2 more

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

University of UtahLead Sponsor

1,098 Previous Clinical Trials

1,778,600 Total Patients Enrolled

Christopher B. Hansen, M.D.Principal InvestigatorUniversity of Utah MidValley Dermatology

Media Library

UVA-1 Therapy (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04922736 — N/A

Systemic Scleroderma Research Study Groups:

Systemic Scleroderma Clinical Trial 2023: UVA-1 Therapy Highlights & Side Effects. Trial Name: NCT04922736 — N/A

UVA-1 Therapy (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04922736 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies open for participants in this clinical trial?

"According to clinicaltrials.gov, this particular medical trial is no longer actively recruiting and was last updated on November 1st 2022. Despite that, there are still 293 trials out of many that require patient participation as of now."

Answered by AI

Recent research and studies

Arthritis & RheumatologyJournal

Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase <scp>ii</scp> Investigator‐initiated, Multicenter, Double‐blind, Randomized, Placebo‐controlled Trial

Khanna, Dinesh, Cathie Spino, Sindhu Johnson, Lorinda Chung, Michael L. Whitfield, Christopher P. Denton, Veronica Berrocal, et al.. 2019. “Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase ii Investigator‐initiated, Multicenter, Double‐blind, Randomized, Placebo‐controlled Trial”. Arthritis & Rheumatology. Wiley. doi:10.1002/art.41055.

Frontiers in MedicineJournal

Ultraviolet A1 Phototherapy for Fibrosing Conditions

Gambichler, Thilo, and Lutz Schmitz. 2018. “Ultraviolet A1 Phototherapy for Fibrosing Conditions”. Frontiers in Medicine. Frontiers Media SA. doi:10.3389/fmed.2018.00237.

Scandinavian Journal of Medicine & Science in SportsJournal

Effect of a Tailored Home‐based Exercise Program in Patients with Systemic Sclerosis: A Randomized Controlled Trial

Filippetti, Mirko, Lucia Cazzoletti, Francesco Zamboni, Pietro Ferrari, Cristian Caimmi, Nicola Smania, Stefano Tardivo, and Marcello Ferrari. 2020. “Effect of a Tailored Home‐based Exercise Program in Patients with Systemic Sclerosis: A Randomized Controlled Trial”. Scandinavian Journal of Medicine & Science in Sports. Wiley. doi:10.1111/sms.13702.

Journal of Scleroderma and Related DisordersJournal